{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:46:13Z","timestamp":1793108773640,"version":"4.5.0"},"reference-count":102,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/14656566.2023.2228686","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T05:13:43Z","timestamp":1687583623000},"page":"1463-1489","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"first","affiliation":[{"name":"Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark"},{"name":"Department of Public Health, Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark"},{"name":"Child and Adolescent Mental Health Centre, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA"},{"name":"Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx090"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2076"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00039-0"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20994"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.07.018"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1543409"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.09.014"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2018.03.006"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.499125"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S167394"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S167485"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00861-6"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12117tx3c"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13024tx4c"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08946"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12546"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00293-4"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.0508e14"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0122"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510040-00003"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000783"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5"},{"key":"cit0027","volume-title":"Stahl\u2019s essential psychopharmacology: prescriber\u2019s guide","author":"Stahl SM","year":"2017"},{"key":"cit0028","unstructured":"Lundbeck Canada Inc. Fluanxol Depot (flupenthixol decanoate) [product monograph] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/canada\/products\/files\/fluanxol_product_monograph_english.pdf."},{"key":"cit0029","unstructured":"APP Pharmaceuticals. Fluphenazine decanoate [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/071413s019lbl.pdf."},{"key":"cit0030","unstructured":"Janssen Pharmaceuticals Companies. Haldol Decanoate (haloperidol decanoate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/HALDOL+Decanoate-pi.pdf."},{"key":"cit0031","unstructured":"European Medicines Agency. Summary of product characteristics: haldol and associated names (haloperidol) [Internet]. [cited 2021 Dec 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/haldol-article-30-referral-annex-iii_en.pdf."},{"key":"cit0032","unstructured":"Orion Pharma. Perphenazine decanoate [summary of product characteristics [Internet]. [cited 2022 Apr 23]. Available from: www.produktresume.dk."},{"key":"cit0033","unstructured":"Lundbeck Canada Inc. Clopixol Depot (zuclopenthixol decanoate) [product monograph] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/canada\/products\/files\/clopixol_product_monograph_english.pdf."},{"key":"cit0034","unstructured":"Otsuka Pharmaceutical Co., Ltd. Abilify Maintena (aripiprazole monohydrate) [US prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.otsuka-us.com\/media\/static\/Abilify-M-PI.pdf?_ga=2.37700576.1548399021.1559037290-53464514.1559037290."},{"key":"cit0035","unstructured":"European Medicines Agency. Abilify Maintena (aripirazole monohydrate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abilify-maintena."},{"key":"cit0036","unstructured":"Otsuka Pharmaceutical Co., Ltd. Abilify Asimtufii (aripiprazole monohydrate) [US prescribing information]."},{"key":"cit0037","unstructured":"Alkermes, Inc. Aristada (aripirazole luaroxil) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.aristada.com\/downloadables\/ARISTADA-PI.pdf."},{"key":"cit0038","unstructured":"Alkermes, Inc. Aristada Initio (aripiprazole luaroxil) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.aristada.com\/downloadables\/ARISTADA-INITIO-PI.pdf."},{"key":"cit0039","unstructured":"Lilly USA, LLC. Zyprexa Relprevv - Prescribing information [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022173s015lbl.pdf."},{"key":"cit0040","unstructured":"European Medicines Agency. Zypadhera (olanzapine pamoate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zypadhera-epar-product-information_en.pdf."},{"key":"cit0041","unstructured":"Janssen Pharmaceuticals Companies. Invega Sustenna (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+SUSTENNA-pi.pdf."},{"key":"cit0042","unstructured":"European Medicines Agency. Xeplion (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeplion-epar-product-information_en.pdf."},{"key":"cit0043","unstructured":"Janssen Pharmaceuticals Companies. Invega Trinza (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+TRINZA-pi.pdf."},{"key":"cit0044","unstructured":"European Medicines Agency. Trevicta (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trevicta-epar-product-information_en.pdf."},{"key":"cit0045","unstructured":"Janssen Pharmaceuticals. Invega Hafyera (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+HAFYERA-pi.pdf."},{"key":"cit0046","unstructured":"European Medicines Agency. Byannli (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byannli-previously-paliperidone-janssen-cilag-international-epar-product-information_en.pdf."},{"key":"cit0047","unstructured":"Janssen Pharmaceuticals. Risperdal Consta (risperidone microspheres) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/RISPERDAL+CONSTA-pi.pdf."},{"key":"cit0048","unstructured":"Shandong Luye Pharmaceutical Co., Ltd. Rykindo (risperidone) for extended-release injectable suspension for intramuscular use [prescribing information] [Internet]. [cited 2023 May 2]. Available from: https:\/\/www.luye.cn\/lvye_en\/rykindo.pdf."},{"key":"cit0049","unstructured":"Indivior Inc. Perseris (risperidone) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.perserishcp.com\/prescribing-information.pdf."},{"key":"cit0050","unstructured":"European Medicines Agency. Okedi (subcutaneous risperidone) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/okedi-epar-product-information_en.pdf."},{"key":"cit0051","unstructured":"Teva Neuroscience Inc. Uzedy (risperidone) extended-release injectable suspension for subcutaneous use [prescribing information] [Internet]. [cited 2023 Apr 29]. Available from: https:\/\/www.uzedy.com\/globalassets\/uzedy\/prescribing-information.pdf."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw116"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s13"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.811984"},{"key":"cit0055","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor D","year":"2019","edition":"13"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20579"},{"key":"cit0057","volume-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical application","author":"Stahl SM","year":"2013","edition":"4"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.009"},{"issue":"16","key":"cit0059","first-page":"18","volume":"64","author":"Ereshefsky L","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000840"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1121809"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09741"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1006356"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.041"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1965974"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000249"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000691"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1371014"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919000816"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0447-7"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000921"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0488-4"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000040"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.116.004382"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-10-45"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1515915"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.144"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000203"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.141"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.CI.101118"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab091"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.4109"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00078-X"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00158-4"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.117"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719001296"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.11.025"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30264-9"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001098"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1017\/S109285291900124X"},{"key":"cit0092","volume-title":"Subcutaneous risperidone (TV-46000) efficacy and safety in schizophrenia: a phase 3, randomized, double-blind, relapse prevention study (RISE Study)","author":"Kane JM","year":"2022"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21056"},{"key":"cit0094","unstructured":"Otsuka Pharmaceutical Co., Ltd. NCT05119894: a multicenter, open-label, clinical pharmacology trial to determine the pharmacokinetics, tolerability, and safety of brexpiprazole Long Acting Injectable (LAI) administered as a single dose in patients with schizophrenia [Internet]. 2021 [cited 2022 Apr 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05119894."},{"key":"cit0095","unstructured":"Intra-Cellular Therapies, Inc. NCT04709224: an Open-label Study to Determine the Pharmacokinetics, Safety and Tolerability of Single Ascending Doses of a Subcutaneous Injection of Lumateperone Long-Acting Injectable (LAI) Formulation in Patients with Schizophrenia [Internet]. 2022 [cited 2022 Apr 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04709224."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.06.036"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.02.004"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S159704"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S210340"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3109\/09638237.2014.973102"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00192-x"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2228686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T09:45:09Z","timestamp":1690969509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2228686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":102,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/14656566.2023.2228686"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2228686","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}